Zealand Pharma A/S
ZEAL
Clasificación en acciones
#5477
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the... Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Precio por acción
$35.84
Última sincronización: 2026-10-16
Capitalización bursátil
$2.49B
Cambio (1 día)
-1.27%
Cambio (1 año)
-49.95%
País
DK
Comercio Zealand Pharma A/S (ZEAL)
Categoría
Healthcare
Capitalización de mercado de Zealand Pharma A/S(ZEAL)
Capitalización bursátil: $2.49B
A fecha de October 2026, Zealand Pharma A/S tiene una capitalización de mercado de $2.49B. Esto convierte a Zealand Pharma A/S en la 5477th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Zealand Pharma A/S desde 2013 hasta 2026
ZEAL en comparación con los más populares 5 títulos stocks
